Antisense oligonucleotide preparation method

Details Antisense oligonucleotide preparation method Antisense oligonucleotide preparation method

2005-12-06

2005-12-06

Shukla, Ram R. (Department: 1635)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091100, C435S091500, C536S023100, C536S024500

Reexamination Certificate

active

06972171

ABSTRACT:
A method for the preparation of an antisense oligonucleotide or derivative thereof comprising the steps of: selecting a target nucleic acid, if necessary elucidating its sequence; generating the antisense oligonucleotide with the proviso that: the oligonucleotide comprises at least 8 residues; the oligonucleotide comprises at maximum twelve elements, which are capable of forming three hydrogen bonds each to cytosine bases; the oligonucleotide does not contain four or more consecutive elements, capable of forming three hydrogen bonds each with four consecutive cytosine bases (CCCC) within the target molecule or alternatively four or more consecutive elements of GGGG; the oligonucleotide does also not contain 2 or more series of three consecutive elements, capable of forming three hydrogen bonds each with three consecutive cytosine bases (CCC) within the target molecule, or alternatively 2 or more series of three consecutive elements of GGG; and the ratio between residues forming two hydrogen bonds per residue (2H-bond-R) with the target molecule and those residues forming three hydrogen bonds per residue (3H-bond-R) with the target molecule, is ruled by the following specifications: 3H-bond-R/3H-bond-R+2H-bond-R≧0.29, and synthesizing the oligonucleotide thus generated in a per se known manner.

REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5948888 (1999-09-01), de la Monte et al.
patent: WO90/10030 (1990-09-01), None
patent: WO93/07883 (1993-04-01), None
patent: WO94/25588 (1994-11-01), None
patent: WO95/00103 (1995-01-01), None
patent: WO95/02422 (1995-01-01), None
patent: WO96/31600 (1996-10-01), None
patent: WO96/39415 (1996-12-01), None
Stull et al. Nucleic Acids Res. (1992) vol. 20, No. 13: 3501-3508.
Probst et al. Trends in Gen. (1996) vol. 12, No. 8: 290-291.
Toon F.C.M. Smetsers et al., Sense and Nucleic Acid Drug Development, 6: pp. 63-67.
Stanley T. Crooke, Therapeutic Applications of Oligonucleotides, Annu. Rev. Pharmacol. Toxicol, 1992, 32, pp. 329-376.
James, W. Antiviral Chem. and Chemotherapy, vol. 2, No. 4, pp. 191-214, 1991.
Milner et al. Nature Biotech., vol. 15, pp. 537-541. 1997.
Ehrlich et al. Antisense Res. and Dev., vol. 4, pp. 173-183, 1994.
Vaerman et al. Blood, vol. 90, No. 1, pp. 331-339, 1997.
Branch, A. Trends in Biochem. Sci., vol. 23, pp. 45-50, 1997.
Crooke, S.T. Antisense Res. and Application, Chapter 1, pp. 1-50, Published by Springer-Verlag, 1998.
Verma et al. Nature, vol. 389, pp. 239-243, 1997.
Crystal, R.G. Science, vol. 270, pp. 404-410, 1995.
Friedmann, T. Scientific American, June Volume, pp. 96-101, 1997.
Yu et al., “Hybrid Oligonucleotides: Synthesis, Biophysical Properties, Stability Studies, and Biological Activity,”Bioorganic&Medicinal Chemistry, 4 (10) : 1685-1692 (1996).
Zhao et al., “Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation,”Biochemical Pharmacology, 51 (2) : 173-182 (1996).
Hatzfeld, “Release of Early Human Hematopoietic Progenitors from Quiescence by Antisense Transforming Growth Factor β1 or Rb Oligonucleotides,”Journal of Experimental Medicine, 174 (4) : 925-929 (1991).
Fitzpatrick, et al., “Antisense Oligonucleotides Specific for Transforming Growth Factor β2 Inhibit the Growth of Malignant Mesothelioma Both in Vitro and in Vivo,”Cancer Research, 57 : 3200-3207 (1997).
Pisetsky et al., “Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligonucleotides, ”Molecular Biology Reports, 18 (3) :217-221 (1993).
Jachimczak et al., “Transforming growth factor β-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides,”International Journal of Cancer, 65 (3) :332-337 (1996).
Jachimczak et al., “The effect of transforming growth factor β2-specific phosphorothioate-anti-sense oligonucleotides in reversing cellular immunosuppression in malignant glioma,” 78 : 944-951 (1993).
Agrawal, “Antisense oligonucleotides: towards clinical trials,”Trends in Biotechnology, 14(10) :376-387 (1996).

Affiliated with

Also associated with

Rating

Antisense oligonucleotide preparation method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense oligonucleotide preparation method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotide preparation method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3486426